BLTE
BELITE BIO, INC
NASDAQ · Healthcare · Biotechnology · US
$170.96
+0.36%Next report
Analyst consensus
- Next report date
- Nov 9, 2026
- EPS estimate
- -$0.79
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.70
- EPS estimate
- -$0.73
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +7.5%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $252
- PT range
- $206 – $303
- Analysts
- 5
5 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.73 | -$0.70 | Beat 4.11% | — |
| May 20, 2026 | -$0.60 | -$0.34 | Beat 43.33% | — |
| Mar 17, 2025 | -$0.30 | -$0.32 | Miss -6.67% | — |
| Aug 9, 2024 | -$0.28 | -$0.31 | Miss -10.71% | — |
| Mar 11, 2024 | -$0.36 | -$0.25 | Beat 30.56% | — |
| Nov 13, 2023 | -$0.31 | -$0.40 | Miss -29.03% | — |
| Mar 31, 2023 | -$0.22 | -$1.04 | Miss -374.41% | — |
| Sep 29, 2022 | — | -$0.10 | — | — |
| Apr 29, 2022 | — | -$0.26 | — | — |
| Mar 31, 2022 | — | -$0.05 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 9, 2026